Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.8)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2020, vol. 29, nr 10, October, p. 1231–1236

doi: 10.17219/acem/125431

Publication type: review

Language: English

License: Creative Commons Attribution 3.0 Unported (CC BY 3.0)

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Adalimumab in the treatment of non-infectious uveitis

Alicja Burek-Michalska1,D, Anna Turno-Kręcicka2,E,F

1 University Hospital in Wrocław, Poland

2 Chair and Clinic of Ophthalmology, Wroclaw Medical University, Poland

Abstract

Non-infectious uveitis (NIU) is a serious sight-threatening condition whose pathogenesis is often autoimmune in nature. It may manifest in any age group, though adults aged 20–50 are the group most often affected. It causes 5–10% of visual impairment worldwide. The epidemiology of some specific uveitis diseases varies worldwide, because they are influenced by genetic, environmental and socioeconomic factors. It can occur only in the eye or as a symptom of a systemic condition. The most common cause of NIU is HLA-B-27-associated anterior uveitis (4–32%). The standard treatment for NIU is a local, topical and systemic steroid therapy in combination with immunomodulatory therapy. However, recently, a new drug – adalimumab, which is a tumor necrosis factor α (TNF-α) inhibitor – was approved by FDA in the treatment of NIU and is increasingly used to treat various conditions. Adalimumab has been proven in many studies to be safe and effective in the treatment of NIU associated with diverse systemic diseases.

Key words

non-infectious uveitis, adalimumab, biologic therapy, TNF-α inhibitors

References (36)

  1. Hasegawa E, Takeda A, Yawata N, Sonoda KH. The effectiveness of adalimumab treatment for non-infectious uveitis. Immunol Med. 2019;42(2):79–83. doi:10.1080/25785826.2019.1642080
  2. Tsirouki T, Dastiridou A, Symeonidis C, et al. A focus on the epidemiology of uveitis. Ocul Immunol Inflamm. 2018;26(1):2–16. doi:10.1080/09273948.2016.1196713
  3. Ming S, Xie K, He H, Li Y, Lei B. Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: A meta-analysis and systematic review. Drug Des Devel Ther. 2018;12:2005–2016. doi:10.2147/DDDT.S160431
  4. Goto H, Zako M, Namba K, et al. Adalimumab in active and inactive, non-infectious uveitis: Global results from the VISUAL I and VISUAL II trials. Ocul Immunol Inflamm. 2019;27(1):40–50. doi:10.1080/09273948.2018.1491605
  5. LaMattina KC, Goldstein DA. Adalimumab for the treatment of uveitis. Expert Rev Clin Immunol. 2017;13(3):181–188. doi:10.1080/1744666X.2017.1288097
  6. Bitossi A, Bettiol A, Silvestri E, et al. Adalimumab accounts for long-term control of noninfectious uveitis also in the absence of concomitant DMARD treatment: A multicenter retrospective study. Mediators Inflamm. 2019;2019:1623847. doi:10.1155/2019/1623847
  7. Leal I, Rodrigues FB, Sousa DC, et al. Anti-TNF drugs for chronic uveitis in adults: A systematic review and meta-analysis of randomized controlled trials. Front Med (Lausanne). 2019;6:104. doi:10.3389/fmed.2019.00104
  8. Sheppard J, Joshi A, Betts KA, et al. Effect of adalimumab on visual functioning in patients with noninfectious intermediate uveitis, posterior uveitis, and panuveitis in the VISUAL-1 and VISUAL-2 trials. JAMA Ophthalmol. 2017;135(6):511–518. doi:10.1001/jamaophthalmol.2017.0603
  9. Hu S, Liang S, Guo H, et al. Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor α-associated diseases from a molecular view. J Biol Chem. 2013;288(38):27059–27067. doi:10.1074/jbc.M113.491530
  10. Rifkin LM, Birnbaum AD, Goldstein DA. TNF inhibition for ophthalmic indications: Current status and outlook. BioDrugs. 2013;27(4):347–357. doi:10.1007/s40259-013-0022-9
  11. Cordero-Coma M, Sobrin L. Antitumor necrosis factor-α therapy in uveitis. Surv Ophthalmol. 2015;60(6):575–589. doi:10.1016/j.survophthal.2015.06.004
  12. Goldhardt R, Rosen BS. Uveitic macular edema: Treatment update. Curr Ophthalmol Rep. 2016;4(1):30–37. doi:10.1007/s40135-016-0090-3
  13. Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943. doi:10.1056/NEJMoa1509852
  14. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda APM. Adalimumab: Long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. 2013;72(4):517–524. doi:10.1136/annrheumdis-2011-201244
  15. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54(3):692–701. doi:10.1002/art.21675
  16. Hellgren K, Smedby KE, Feltelius N, Baecklund E, Askling J. Do rheumatoid arthritis and lymphoma share risk factors? A comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis. Arthritis Rheum. 2010;62(5):1252–1258. doi:10.1002/art.27402
  17. Suhler EB, Adán A, Brézin AP, et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology. 2018;125(7):1075–1087. doi:10.1016/j.ophtha.2017.12.039
  18. Martin TM, Rosenbaum JT. An update on the genetics of HLA-B27-associated acute anterior uveitis. Ocul Immunol Inflamm. 2011;19(2):108–114. doi:10.3109/09273948.2011.559302
  19. Pérez-Guijo V, Santos-Lacomba M, Sánchez-Hernández M, Castro-Villegas MDC, Gallardo-Galera JM, Collantes-Estévez E. Tumour necrosis fac-tor-alpha levels in aqueous humour and serum from patients with uveitis: The involvement of HLA-B27. Curr Med Res Opin. 2004;20(2):155–157. doi:10.1185/030079903125002847
  20. Rudwaleit M, Rødevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: Results of a prospective open-label study. Ann Rheum Dis. 2009;68(5):696–701. doi:10.1136/ard.2008.092585
  21. Kim M, Won JY, Choi SY, Ju JH, Park YH. Anti-TNFα treatment for HLA-B27-positive ankylosing spondylitis-related uveitis. Am J Ophthalmol. 2016;170:32–40. doi:10.1016/j.ajo.2016.07.016
  22. Nunes H, Bouvry D, Soler P, Valeyre D. Sarcoidosis. Orphanet J Rare Dis. 2007;2:46. doi:10.1186/1750-1172-2-46
  23. Pasadhika S, Rosenbaum JT. Ocular sarcoidosis. Clin Chest Med. 2015;36(4):669–683. doi:10.1016/j.ccm.2015.08.009
  24. Erckens RJ, Mostard RLM, Wijnen PAHM, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012;250(5):713–720. doi:10.1007/s00417-011-1844-0
  25. Riancho-Zarrabeitia L, Calvo-Río V, Blanco R, et al. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients. Semin Arthritis Rheum. 2015;45(3):361–368. doi:10.1016/j.semarthrit.2015.05.010
  26. Zeidan MJ, Saadoun D, Garrido M, Klatzmann D, Six A, Cacoub P. Behçet’s disease physiopathology: A contemporary review. Auto Immun Highlights. 2016;7(1):4. doi:10.1007/s13317-016-0074-1
  27. Gül A. Pathogenesis of Behçet’s disease: Autoinflammatory features and beyond. Semin Immunopathol. 2015;37(4):413–418. doi:10.1007/s00281-015-0502-8
  28. Fabiani C, Vitale A, Emmi G, et al. Efficacy and safety of adalimumab in Behçet’s disease-related uveitis: A multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):183–189. doi:10.1007/s10067-016-3480-x
  29. Minos E, Barry RJ, Southworth S, et al. Birdshot chorioretinopathy: Current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatment. Orphanet J Rare Dis. 2016;11(1):61. doi:10.1186/s13023-016-0429-8
  30. Cunningham ET, Levinson RD, Denniston AK, Brézin AP, Zierhut M. Birdshot chorioretinopathy. Ocul Immunol Inflamm. 2017;25(5):589–593. doi:10.1080/09273948.2017.1400800
  31. Huis Het Veld PI, van Asten F, Kuijpers RWAM, Rothova A, de Jong EK, Hoyng CB. Adalimumab therapy for refractory birdshot chorioretinopathy. Retina. 2019;39(11):2189–2197. doi:10.1097/IAE.0000000000002281
  32. Steeples LR, Spry P, Lee RWJ, Carreño E. Adalimumab in refractory cystoid macular edema associated with birdshot chorioretinopathy. Int Ophthalmol. 2018;38(3):1357–1362. doi:10.1007/s10792-017-0592-5
  33. Chu XK, Chan C-C. Sympathetic ophthalmia: To the twenty-first century and beyond. J Ophthalmic Inflamm Infect. 2013;3(1):49. doi:10.1186/1869-5760-3-49
  34. Chang GC, Young LH. Sympathetic ophthalmia. Semin Ophthalmol. 2011;26(4–5):316–320. doi:10.3109/08820538.2011.588658
  35. Kim JB, Jeroudi A, Angeles-Han ST, Grossniklaus HE, Yeh S. Adalimumab for pediatric sympathetic ophthalmia. JAMA Ophthalmol. 2014;132(8):1022–1024. doi:10.1001/jamaophthalmol.2014.426
  36. Hiyama T, Harada Y, Kiuchi Y. Effective treatment of refractory sympathetic ophthalmia with glaucoma using adalimumab. Am J Ophthalmol Case Rep. 2019;14:1–4. doi:10.1016/j.ajoc.2019.01.009
© Wroclaw Medical University